ARROWHEAD PHARMACEUTICALS, INC. Unrealized Loss on Securities
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) reported Unrealized Loss on Securities of $283.38 thousand for the 6-month period ending 2014-03-31, per its 10-Q filed 2014-05-06.
Discontinued › Notes
us-gaap:UnrealizedLossOnSecurities · last filed 2014-05-06
- ARROWHEAD PHARMACEUTICALS, INC. unrealized loss on securities for the quarter ending 2014-03-31 was $66.16K.
- ARROWHEAD PHARMACEUTICALS, INC. unrealized loss on securities for the quarter ending 2013-12-31 was $217.22K.
- ARROWHEAD PHARMACEUTICALS, INC. unrealized loss on securities for the quarter ending 2013-09-30 was $24.43K.
| Period end | Unrealized Loss on Securities 3 month | Unrealized Loss on Securities 6 month | Unrealized Loss on Securities 9 month | Unrealized Loss on Securities 12 month |
|---|---|---|---|---|
| 2014-03-31 | $66.16K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-05-06 | $283.38K 10-Q · filed 2014-05-06 | $307.81K derived: sum of 3 quarters · filed 2014-05-06 | |
| 2013-12-31 | $217.22K 10-Q · filed 2014-02-04 | $241.65K derived: sum of 2 quarters · filed 2014-05-06 | ||
| 2013-09-30 | $24.43K derived: 10-Q 12 month − 10-Q 9 month · filed 2014-05-06 | $41.64K 10-Q · filed 2014-05-06 | ||
| 2013-06-30 | $17.21K 10-Q · filed 2013-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |